Stay updated with breaking news from Brainstorm Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Friday. The firm issued a hold rating on the biotechnology company’s stock. Brainstorm Cell Therapeutics Stock Down 7.0 % BCLI stock opened at $0.54 on Friday. Brainstorm Cell Therapeutics has a 52-week low of $0.13 and […]
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,990,000 shares, an increase of 48.5% from the March 31st total of 1,340,000 shares. Based on an average daily volume of 987,100 shares, the short-interest […]
Brainstorm Cell (NASDAQ: ) just reported results for the fourth quarter of 2023. InvestorPlace Earnings is a project that leverages data from TradeSmith to…
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ:BCLI opened at $0.39 on Wednesday. Brainstorm Cell Therapeutics has a one year low of $0.13 […]
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 2,390,000 shares, a decline of 43.2% from the December 31st total of 4,210,000 shares. Based on an average trading volume of 2,600,000 shares, the days-to-cover […]